Follicular Lymphoma

Faculty Roundtable on CAR T-cell Therapies, Bispecific Antibodies & Antibody-Drug Conjugates in FL
Faculty Roundtable on CAR T-cell Therapies, Bispecific Antibodies & Antibody-Drug Conjugates in FL
CME, CPE, CNE
Loretta J. Nastoupil, MD and Catherine S. Diefenbach, MD
Release Date: March 09, 2023
Expiration Date: March 09, 2024

Although follicular lymphoma (FL) often responds well to initial therapy, many patients will relapse, and a considerable proportion of patients experience disease progression within 24 months. In this activity, Drs. Nastoupil and Diefenbach address the recent advances in FL-directed CAR T-cell therapies, bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs). They will also discuss safety and efficacy data from ongoing clinical trials, and how to incorporate recently approved and emerging novel targeted therapies into individualized treatment strategies.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
CE ExpiredView Only, No Credit
 

Spotlight on Relapsed/Refractory Follicular Lymphoma
Spotlight on Relapsed/Refractory Follicular Lymphoma
CME, CPE
James O. Armitage, MD; and Reid W. Merryman, MD
Release Date: December 09, 2022
Expiration Date: December 09, 2023

In this activity, Dr. Merryman will address the expanding landscape in the treatment of follicular lymphoma and, along with Dr. Armitage, they will discuss the current standard of care. Dr. Merryman will provide a comprehensive overview of the emerging data in the relapsed setting and discuss the current placement of those agents in the future treatment paradigm with a discussion of potential impact to patient care and outcomes.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
CE ExpiredView Only, No Credit
 

Current and Emerging Directions in the Frontline Treatment of Follicular Lymphoma: Implications for Practice
Current and Emerging Directions in the Frontline Treatment of Follicular Lymphoma: Implications for Practice
CME, CPE
James O. Armitage, MD; and Gilles Salles, MD, PhD
Release Date: October 19, 2022
Expiration Date: October 19, 2023

In this activity, Dr. Salles will address current and emerging directions in the frontline treatment of follicular lymphoma, he will also discuss recent evidence on emerging therapies and describe implications for current and future practice. To conclude, Dr. Armitage and Dr. Salles examine how to apply these therapies to practice and how to individualize therapy for patients.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
CE ExpiredView Only, No Credit